Name

Shijiazhuang Hipro Biotechnology Co.

Legal name

Hipro Biotechnology Co.,Ltd

Website

https://hipro.us

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics / Point-of-Care Testing

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Point-of-care diagnostics
• Immunoassay analyzers
• In vitro diagnostics
• Diagnostic test reagents
• Home diagnostic testing

Headquarters

HQ city

Shijiazhuang

HQ country

China

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Point-of-Care Diagnostic Instruments and Reagents: Sale of immunoassay analyzers (A1, A1 Plus, HP-AFS series, PalmF, Hurricane, SimplyRead, Microfluidics) and配套 diagnostic reagents for various disease categories including cardiovascular, infection, renal function, diabetes, and more
2. Licensing Royalties: 20% royalty on net sales from Qlife for Egoo platform products commercialized in China; exclusive licensing agreement for technology transfer
3. Technology Licensing to Partners: Integration of FDA-approved HbA1c test with Qlife's Egoo platform under exclusive commercial agreement for EU and US distribution

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Shijiazhuang Hipro Biotechnology Co. manufactures and sells point-of-care testing (POCT) diagnostic instruments and reagents, including automated immunoassay analyzers (Hurricane, HP-AFS series, SimplyRead), a microfluidics immunoassay system (DX-1), portable fluorescence immunoassay analyzers (PalmF, Palm Reader), colloidal gold home test kits (ZOAN), and a broad menu of 75+ diagnostic reagent parameters covering cardiovascular, infection, renal, gastric, liver, hormone, tumor marker, and diabetes testing. The company distributes its products globally to hospitals, laboratories, primary care clinics, and individual consumers through a network spanning 100+ countries.

Product overview

Hipro Biotechnology is a point-of-care testing (POCT) manufacturer offering a comprehensive portfolio of diagnostic products. The portfolio includes immunoassay analyzers (Hurricane, HP-AFS/1, HP-AFS/3, HP-AFS/1-PLUS, SimplyRead, PalmF, Palm Reader), microfluidics systems (DX-1), home test products (ZOAN platform), and diagnostic reagents covering Infection, Cardiovascular, Renal Function, Gastric Function, Liver, Autoimmunity, Hormone, Tumor Marker, Microelement, and Diabetes testing. The company distributes products across 100+ countries with 75+ parameters and holds 212 authorized patents.

Differentiator

Problem solved

Functional benefit

Brands

• PalmF: Portable fluorescence immunoassay analyzer for point-of-care testing, suitable for primary care and personal health management with tests for diabetes, cardiac conditions, vitamins, and female reproductive hormones
• Hurricane
• ZOAN
• A1
• HP-AFS Series
• DX-1 Microfluidics

Products and services

• Hurricane Immunoassay Analyzer A specific protein immunoassay analyzer with high accuracy, wide linear range, and high sensitivity, designed for clinical and laboratory point-of-care testing.
• HP-AFS/1 Immunoassay Analyzer A liquid-based specific protein testing immunoassay analyzer known for stability and advanced performance in clinical laboratories.
• HP-AFS/3 Immunoassay Analyzer A liquid-based specific protein testing immunoassay analyzer tailored for varying demands of medical institutions and laboratories.
• HP-AFS/1-PLUS Immunoassay Analyzer An automated immunoassay system with multi-methodologies, intelligent temperature control technology, and throughput of up to 100 tests/hour.
• SimplyRead Immunoassay Analyzer A protein analyzer with simple operation designed for point-of-care testing in primary care and small laboratory settings.
• DX-1 Microfluidics Immunoassay System An advanced microfluidics immunoassay system using Hipro's proprietary 'reagent jet' liquid phase microfluidic platform, enabling fast and efficient detection by precisely controlling the flow of small liquid volumes within microchannels.
• PalmF Fluorescence Immunoassay Analyzer A portable fluorescence immunoassay analyzer with wide linearity, high sensitivity, dual calibration, and intelligent result interpretation, suitable for point-of-care testing in primary care and small to medium-sized laboratories.
• Palm Reader Fluorescence Immunoassay Analyzer Platform A fluorescence immunoassay analyzer platform with 25+ reagent types focused on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other biomarkers.
• ZOAN Home Test Platform A colloidal gold test platform for home use with integrated design, easy operation, rapid results, and no leakage; includes Fecal Occult Blood/Transferrin (FOB+TRF), Calprotectin, H.pylori Antigen, and Early Pregnancy test kits for consumer self-testing.
• Glycohemoglobin (HbA1c) Test Kit FDA 510(k) cleared and NGSP certified test kit for clinical determination of glycosylated hemoglobin (HbA1c) in human blood, using antigen-antibody reaction and latex agglutination technology; whole-blood specimen, 300-second test time, 25 tests per kit, with best-in-class precision (CV below 3%).
• Infection Test Reagent Panel Reagent panel for detecting infections and inflammatory conditions, including High Sensitivity C-Reactive Protein (CRP), Full Range CRP, Procalcitonin (PCT), and Serum Amyloid A (SAA) test kits.
• Cardiovascular Test Reagent Panel Panel of 12 cardiovascular biomarkers including H-FABP, Myo, cTnI, CK-MB, NT-proBNP, HCY, LP(a), D-Dimer, Lp-PLA2, HDL-C, and LDL-C for cardiovascular disease detection.
• Renal Function Test Reagent Panel Renal function panel including Microalbumin (mAlb), Cystine (CysC), NGAL, β1-MG, β2-MG, and Retinol Binding Protein (RBP) tests for kidney function assessment.
• Gastric Function Test Reagent Panel Gastric function panel including Calprotectin, Pepsinogen I (PGI), and Pepsinogen II (PGII) tests for gastric health monitoring and early gastric cancer screening.
• Liver Test Reagent Panel Liver function panel including Prealbumin (PA), Transferrin (TRF), Adenosine Deaminase (ADA), Complement 3 (C3), and Complement 4 (C4) tests.
• Autoimmunity Test Reagent Panel Autoimmunity panel including Immune Globulin A (IgA), IgM, IgE, and IgG tests for immune function evaluation.
• Hormone Test Reagent Panel Hormone panel including TSH, TT3, TT4, and HCG tests for thyroid and reproductive hormone assessment.
• Tumor Marker Test Reagent Panel Tumor marker panel including CEA and AFP tests for cancer marker detection.
• Quality Control System Quality control solutions for ensuring accuracy and reliability of diagnostic testing across Hipro's immunoassay analyzer and reagent product lines.
• Egoo Health Blood Testing Platform An AI-driven personalized home blood testing platform developed under the exclusive licensing arrangement with Qlife Holding AB, with Hipro responsible for development, regulatory submissions, manufacturing, and commercialization of the Egoo medical technology platform in China; integrates the FDA-approved HbA1c test and supports AI-driven diabetes and MASLD management in partnership with Beijing Tsinghua Changgung Hospital.

Quantifiable outcome

• Reduces patient wait time from billing to test results from 2-3 hours to 10 minutes
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and strategic.

• Qlife Holding ABcoreChannel Partner/ Reseller/ Distributor · 16 December 2025Exclusive 20-year commercial agreement (with automatic renewal options) granting Qlife rights to sell and distribute Hipro's products in EU and US markets. Deal includes integration of Hipro's FDA-approved HbA1c test with Qlife's Egoo platform, aiming to expand decentralized healthcare solutions globally.
• Beijing Tsinghua Changgung HospitalstrategicStrategic or Co-development Partner · 1 December 2025Collaboration on AI-driven personalized diabetes management project. Egoo Health blood testing platform part of project launched by Hipro to improve chronic disease management in China, focusing on AI-driven proactive healthcare for diabetes and MASLD using home testing and personalized health management.
• Qlife Holding ABcoreStrategic or Co-development Partner · 1 November 2025Letter of Intent for potential reverse takeover between Hipro Biotechnology and Qlife. After Nasdaq rejection of 'Red Chip' merger structure, companies extended LOI until December 31, 2026 and are exploring alternative transaction structures. Both companies focusing on strengthening collaboration and business synergies in interim.
• Qlife Holding ABcoreStrategic or Co-development Partner · 1 March 2025Exclusive licensing agreement where Hipro assumes full responsibility for development, regulatory submissions, manufacturing, and commercialization of Egoo medical technology platform in China. Qlife receives 20% royalty on net sales. Hipro implementing AI integration and user experience upgrades to Egoo Q300.
• BD (Becton Dickinson)strategicStrategic or Co-development PartnerStrategic cooperation with BD (Becton Dickinson) mentioned in company materials and signing ceremony documentation. Nature of partnership involves POCT diagnostic solutions collaboration.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• QuidelOrtho Corporation: Merged US diagnostics company combining Quidel's rapid POCT (Sofia, Triage) with Ortho's clinical chemistry and immunoassay. Broad incumbent in the same POCT categories Hipro competes in across hospital and primary care.
• Roche Diagnostics: Global diagnostics incumbent with cobas and Accu-Chek franchises spanning centralized immunoassay and POCT. Sets performance and pricing benchmarks that Hipro's immunoassay analyzers are benchmarked against in hospital procurement.
• Siemens Healthineers: Global healthcare major offering ADVIA Centaur, Atellica, and other immunoassay/clinical chemistry platforms. Incumbent that hospitals benchmark against and that Hipro must displace to win large system contracts.
• Becton Dickinson (BD): Major medical device and diagnostics company with BD Veritor POCT platforms and strategic cooperation partner of Hipro. Competes broadly in POCT while also being a partner, creating an ambiguous overlap with Hipro's product portfolio.
• Abbott Diagnostics: Global diagnostics leader offering i-STAT and other POCT platforms alongside centralized lab systems. Operates broadly across immunoassay and clinical chemistry with deep hospital relationships Hipro is competing against.

Emerging players

• EKF Diagnostics: UK-based diagnostics company offering point-of-care analyzers (QuikRead, Hemo Control) and HbA1c testing solutions. Comparable sub-scale POCT competitor with similar focus on primary care and decentralized testing markets.

Direct peers

• Sinocare Inc. China-based diagnostics company specializing in blood glucose monitoring and POCT immunoassay analyzers. Competes head-to-head with Hipro in diabetes testing (HbA1c) and broader POCT reagent panels across emerging and developed markets.
• Wondfo Biotech: Chinese POCT diagnostics manufacturer offering immunoassay analyzers and rapid test reagents across infectious disease, cardiology, and women's health. Direct competitor in same product category with similar China-based global distribution model.
• Yhlo Biotech: Chinese chemiluminescence immunoassay and POCT manufacturer with comparable product breadth across infectious disease, cardiac, and hormone markers. Direct competitor in hospital and clinical laboratory POCT segment.
• Qlife Holding AB: Swedish POCT platform developer (Egoo system) and Hipro's exclusive EU/US distribution partner; potential reverse takeover counterparty. Overlapping immunoassay platform technology and chronic disease management focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/hiprobiotech
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/shijiazhuang-hipro-biotechnology-co-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shijiazhuang Hipro Biotechnology Co.